Trade names Egrifta Routes of
administration Subcutaneous injection | MedlinePlus a611035 ATC code H01AC06 (WHO) | |
 | ||
AHFS/Drugs.com Multum Consumer Information Pregnancy
category US: X (Contraindicated) | ||
Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
References
Tesamorelin Wikipedia(Text) CC BY-SA